
Ascendis Pharma A/S: stock overview
Price
$271.19
November 17, 2026Market cap $16.4B
What Ploutos Investor adds for Ascendis Pharma A/S
Part of Ploutos Investor, €9.99 a month
- The full history: 11 fiscal years, from 2015
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
In short
Ascendis Pharma A/S had revenue of $845M in the fiscal year to December 31, 2025 and a net loss of $268M. Revenue grew by 153.0% a year on average over the last 5 years. It holds more cash than debt, by $488M. It pays no dividend.
From its SEC filings (latest fiscal year to December 31, 2025) and the price of November 17, 2026.
Its SEC filings- Market cap
- $16.4B
- 60.61M shares
- P/E
- –
- Revenue, fiscal year
- $845M
- +153.0% a year over 5 years
- Net margin
- -31.7%
Worth knowing
What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.
3 fiscal years in figures
Each fiscal year's figures as the company filed them, and the share price at its end.
+64.3% a year over 2 years
Fiscal years in figures
ASND's revenue, profit, cash flow and dividend with each year-end price, from 2015 to 2022, 8 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
Key figures
The company's current figures in five groups. Each term is explained behind its ⓘ.
Valuation
- Market cap 3-year median: $8.0B
- $16.4B
- Enterprise value
- $15.9B
- P/E
- –
- EV / EBIT
- –
- EV / Revenue
- 18.9
- P/B
- –
- FCF yield
- –
- Earnings yield 3-year median: -4.9%
- –
Profitability
- Gross margin
- 86.8%
- Operating margin
- -18.9%
- Net margin 3-year median: -104.0%
- -31.7%
- ROIC
- -16.5%
- ROIC, 5-year average
- -44.9%
- ROE
- –
Growth
- Revenue, yearly change
- +98.0%
- EPS, yearly change
- –
- FCF, yearly change
- –
- Revenue, average a year
- +153.0%
The yearly change compares FY2025 with FY2024.
Balance sheet
- Cash
- $1.6B
- Total debt
- $1.1B
- Net cash
- $488M
- Net debt / EBITDA
- –
- Interest cover
- –
- Current ratio
- –
Balance sheet of December 31, 2025.
Returns to shareholders
- Dividend yield
- 0.00%
- Buybacks
- 0.12%
- Total returned
- 0.12%
- Shares, yearly change
- +4.7%
The company at the SEC
How it is registered and when its fiscal year ends.
- Name at the SEC
- Ascendis Pharma A/S
- CIK
- 1612042
- Exchange
- NASDAQ
- Industry (SIC)
- 2834 · Pharmaceutical Preparations
- Fiscal year ends
- December 31
- Latest annual report
- December 31, 2025
- Reporting currency
- EUR
- Shares
- 60.61M
Other companies: Healthcare
The largest companies of the same sector, each with its own page.
- LLYEli Lilly and Company+0,00%Compare with ASND
- JNJJohnson & Johnson+0,00%Compare with ASND
- ABBVAbbVie+0,00%Compare with ASND
- UNHUnitedHealth+0,00%Compare with ASND
- MRKMerck & Company+0,00%Compare with ASND
- AMGNAmgen+0,00%Compare with ASND
- TMOThermo Fisher Scientific+0,00%Compare with ASND
- ABTAbbott Laboratories+0,00%Compare with ASND
The full analysis
What do Ascendis Pharma A/S's filings show?
These are Ascendis Pharma A/S's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
What is ASND's market cap?
Ascendis Pharma A/S's market cap is $16.4B, at a price of $271.19 on November 17, 2026 and 60.61M shares.
How much revenue does ASND have?
Ascendis Pharma A/S had revenue of $845M in the fiscal year to December 31, 2025. Over the last 5 years it changed by +153.0% a year on average.
Does ASND pay a dividend?
No. Ascendis Pharma A/S paid no regular dividend over the last 12 months.
Where do the figures come from?
From Ascendis Pharma A/S's SEC filings (its annual report on 20-F) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.